

Claims

1. Injectable implant for human administration consisting of bioresorbable microspheres or microparticles in suspension in a gel.
- 5 2. Implant according to Claim 1, characterized in that the microspheres or microparticles consist of at least one polymer chosen from the poly- ϵ -caprolactones, the lactic acid polymers, the glycolic acid polymers and the lactic co-glycolic acid polymers.
- 10 3. Implant according to either of Claims 1 and 2, characterized in that the proportion of microspheres or microparticles in the gel is from 50 to 300 g/l, and preferably from 60 to 200 g/l.
- 15 4. Implant according to one of the preceding claims, characterized in that the microspheres or microparticles have a mean diameter of from 5 to 150 μm , and preferably from 20 to 80 μm .
- 20 5. Implant according to one of the preceding claims, characterized in that the microspheres or microparticles are bioresorbable within a period of 1 year to 3 years.
6. Implant according to one of the preceding claims, characterized in that said polymer is a polylactic acid chosen from poly-L-lactic acid, poly-D-lactic acid and mixtures thereof.
- 25 7. Implant according to Claim 6, characterized in that the polylactic acid has a molecular mass of between 70,000 and 175,000 Dalton, and preferably between 120,000 and 170,000 Dalton, an intrinsic viscosity of between 3 and 4 dl/g, and preferably between 3.35 and 3.65 dl/g, a
- 30 percentage of residual monomer <0.1% and a percentage of residual solvents <0.01%.
8. Implant according to one of the preceding claims, characterized in that the gel includes mainly, as gelling agent, carboxymethylcellulose (CMC) or hydroxypropyl-
- 35 methylcellulose (HPMC) at a concentration by weight of 0.1 to 7.5%, and preferably from 0.1 to 5.0%.
9. Freeze-dried product obtained by freeze-drying a product according to one of the preceding claims, and capable of reconstituting an injectable implant by

- 10 -

addition of water for injection.